Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1022387 | 1.00 | ALDH1A1 (0.39) | ALDH1A1LMNATLR8TLR7TAAR1 | |
| SCHEMBL1018342 | 0.99 | ALDH1A1 (0.40) | ALDH1A1LMNATLR8TLR7TAAR1 | |
| SCHEMBL1020304 | 0.95 | ALDH1A1 (0.40) | ALDH1A1LMNATLR8TLR7TAAR1 | |
| SCHEMBL1021673 | 0.90 | TAAR1 (0.42) | ALDH1A1LMNATLR8TLR7TAAR1 | |
| SCHEMBL1021355 | 0.87 | ALDH1A1 (0.43) | ALDH1A1LMNATLR8TLR7TAAR1 | |
| SCHEMBL1020799 | 0.86 | CHRM2 (0.44) | ALDH1A1TLR8TLR7TAAR1HTR6 | |
| SCHEMBL1020605 | 0.86 | CHRM2 (0.44) | ALDH1A1TLR8TLR7TAAR1HTR6 | |
| SCHEMBL1021113 | 0.86 | TAAR1 (0.38) | TLR8TLR7TAAR1HTR6HTR2C | |
| SCHEMBL1020704 | 0.86 | TAAR1 (0.38) | TLR8TLR7TAAR1HTR6HTR2C | |
| SCHEMBL1020759 | 0.85 | SYK (0.37) | ALDH1A1LMNATLR8TLR7TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| EP-2094677-B1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | REMYND NV (BE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | SNCA, PARK7, PRNP | ALDH1A1 608/4885LMNA 1913/4885TLR8 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.